Research Paper Volume 15, Issue 19 pp 10732—10745

Micheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption

class="figure-viewer-img"

Figure 3. Micheliolide inhibited osteoclastogenesis without any cytotoxicity. (A) BMMs were seeded on 96-well plates at a density of 1.5*104 cells/well. Then cells were treated with vehicle or different concentrations (5 ug/ml, 10 ug/ml, 20 ug/ml) of Micheliolide for 48 or 96 hours. The cell viability was measured by CCK-8 kit. (B) Representative TRAP staining images from BMMs treated with vehicle or different concentrations (5 ug/ml, 10 ug/ml, 20 ug/ml) of Micheliolide in osteoclastogenesis medium for 5 days. Scale bar = 200 um. (C) Numbers of TRAP positive multinuclear osteoclasts from different groups. (D) Area of TRAP positive multinuclear osteoclasts from different groups. All data: mean ± SD, n=5, N.S. no significant difference between each group.